PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 27: Articles 13001-13500 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. U.S. religious groups vary in patterns of method use, but not in overall contraceptive prevalence.
  2. The U.S.S.R. in transition: contraception and abortion.
  3. Ugandan women more familiar with traditional contraceptive methods than with modern ones.
  4. The UK Family Planning Research Network [editorial]
  5. Understanding recent changes in contraceptive prevalence in Kenya.
  6. Unintended pregnancies and contraceptive use [letter]
  7. Unintended pregnancies and contraceptive use [letter]
  8. Unintended pregnancies and contraceptive use. Author's reply [letter]
  9. Unintended pregnancies and the use of contraception: changes from 1984 to 1989.
  10. Unite recognition, strengthen measurement and initiate new prospect of the family planning work.
  11. Unmet need and the demand for family planning.
  12. Unmet need for contraception in Sri Lanka.
  13. Unmet need for family planning in developing countries.
  14. Update on the metabolic effects of steroidal contraceptives.
  15. Use of a monthly calendar for collecting retrospective data on contraception: an evaluation of the experimental field studies of the Demographic and Health Surveys (DHS) [Uso de un calendario mensual para recolectar datos retrospectivos sobre anticoncepcion: una evaluacion de los estudios de terreno experimentales de las Encuestas Demograficas de Salud (DHS)]
  16. Use of a supplementary survey of abortion patients to correct contraceptive failure rates for underreporting of abortion.
  17. The use of a uterine sound and tenaculum during the IUD fitting procedure and follow up examination: a survey among family planning doctors.
  18. Use of contraception among women applying for abortion. [Abortsogende kvinders brug af praevention.]
  19. The use of less effective methods of contraception among Turkish couples.
  20. Use of survey data to estimate type, duration and effectiveness of contraceptive use.
  21. User research studies contraceptive decision-making.
  22. Users' perspective on the Norplant contraceptive method. [O sistema anticonceptivo Norplant do ponto de vista das usuarias.]
  23. Using a job aid to assist family planning counseling decision-making in the field.
  24. Using DHS data for family planning program development and evaluation.
  25. Using field visits to improve the quality of family planning, health, and nutrition programs: a supervisor's manual.
  26. Using operations research to improve natural family planning program services, management, and policy.
  27. Using oral contraceptives correctly: progress on package instructions.
  28. Using quantitative data to define natural family planning use: a profile.
  29. Using the DHS calendar history of events to study the dynamics of contraceptive use.
  30. Utilizing grassroots workers in family planning programs in India: prospects and problems.
  31. Vaginitis and cervicitis in family planning. [Vaginitis y cervicitis en planificacion familiar.]
  32. Varicose veins and oral contraceptives. Have all the questions been answered? [Varices et contraceptifs oraux. A-t-on repondu a toutes les questions?]
  33. Vascular insufficiency and oral contraception. [Insuffisance veineuse et contraception orale.]
  34. Vasculitis with cutaneous necrosis induced by oral contraceptive.
  35. Video for family planning.
  36. Viet Nam: accessibility of contraceptives.
  37. In vitro interaction of contraceptive steroids with human liver cytochrome P-450 enzymes.
  38. Voluntary surgical contraception (VSC) in the Philippines. (1989 Follow-Up Survey of VSC Acceptors in the Philippines)
  39. Voluntary Surgical Contraception (VSC) medical monitoring and supervision system: Indonesian experience.
  40. Weekly testosterone injections suppress sperm production, may provide effective contraception.
  41. Were the severe adverse effects on several organs and the marked blood pressure increase caused by oral contraceptives? [Svara biverkningar pa flera organ och kraftig blodtrycksstegring orsakades av p-piller?]
  42. What happens to contraception when anti-abortion laws pass?
  43. Why do Chinese women practice contraception? The case of rural Jilin Province.
  44. A woman's risk of ectopic pregnancy varies according to the contraceptive she chooses.
  45. Women in development and family planning.
  46. Women in development: status, issues, information. Proceedings of the Twenty-Third Annual Conference, Association for Population/Family Planning Libraries and Information Centers--International.
  47. Women's employment, education, and contraceptive behaviour in Kinshasa.
  48. Women's groups and contraceptive use in rural Kenya.
  49. Women's position in the household and their use of family planning and antenatal services. A case study from Kisii district, Kenya.
  50. Women's position in the household and their use of family planning and antenatal services: a case study from Kisii district, Kenya.
  51. Women's savings groups and contraceptive use under Save Program: final report.
  52. Women, birth control and the law.
  53. Worker-client exchanges and contraceptive use in rural Bangladesh.
  54. World family planning and contraceptives under development.
  55. World Health Organization's policy considerations in natural family planning.
  56. Results of a contraceptive prevalence survey in Niamey, Niger.
  57. Risk behaviors for HIV infection in clients of Pennsylvania family planning clinics.
  58. Screening for and treating Chlamydia trachomatis and Neisseria gonorrhoeae before contraceptive use and subsequent pelvic inflammatory infection.
  59. Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
  60. An assessment of contraceptive need in the inner city.
  61. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
  62. Attitudes towards contraceptive implants and injectables among present and former users in Singapore.
  63. Benzalkonium chloride for vaginal contraception -- the vaginal sponge. [Benzalkonium-Chlorid zur vaginalen Kontrazeption -- der Scheidenschwamm.]
  64. Birth interval among breast-feeding women not using contraceptives.
  65. Adolescent contraceptive behavior: an assessment of decision processes.
  66. Adolescent contraceptive method choices.
  67. Breast cancer and combined oral contraceptives: results from a multinational study: the WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
  68. Cardiovascular death among women under 40 years of age using low-estrogen oral contraceptives and intrauterine devices in Finland from 1975 to 1984.
  69. Cells adherent to copper-bearing intrauterine contraceptive devices determined by monoclonal antibodies.
  70. Changes in metabolism induced by oral contraceptives containing desogestrel and gestodene in older women.
  71. Chlamydia trachomatis infection in women attending urban midwestern family planning and community health clinics: risk factors, selective screening, and evaluation of non-culture techniques.
  72. Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease.
  73. Clinical experience with a low-dose oral contraceptive containing gestodene.
  74. Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-keto-desogestrel and ethinylestradiol.
  75. Community participation in national family planning programs: some organizational issues.
  76. A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism.
  77. Conception delay after oral contraceptive use: the effect of estrogen dose.
  78. Contraception and ectopic pregnancy risk.
  79. Contraception with a vaginal ring releasing 3-keto desogestrel and ethinylestradiol.
  80. Contraceptive development and testing in the United States of America.
  81. Contraceptive efficacy of testosterone-induced azoospermia in normal men.
  82. Contraceptive failure in the United States: an update.
  83. Contraceptive failure of the ovulation method of periodic abstinence.
  84. Contraceptive knowledge and practices in Ilorin, Nigeria: 1983-88.
  85. Contraceptive practice in the United States, 1982-1988.
  86. Contraceptive practices and contraceptive failures among women requesting termination of pregnancy.
  87. Contraceptive use in HIV infected women.
  88. Contraceptive vaginal ring -- a rising star on the contraceptive horizon.
  89. The correlation between Chlamydia antigen, antibody, vaginal colonization and contraceptive method in young unmarried women.
  90. Cross-national models of fertility, family planning, and development: testing for reciprocal effects.
  91. Cultural differences in a family planning clinic.
  92. Cycle control on low-dose oral contraceptives: a comparative trial.
  93. The demographic impact of family planning programs.
  94. Development of contraceptives--obstacles and opportunities.
  95. Differences in knowledge of and risk factors for AIDS between Hispanic and non-Hispanic women attending an urban family planning clinic.
  96. Editorial: the contraception / abortion issue: should we get involved? [editorial]
  97. Effect of low-dose oral contraceptive on gonadotropins, androgens, and sex hormone binding globulin in nonhirsute women.
  98. Effect of low-dose oral contraceptives on carbohydrate and lipid metabolism in women with recent gestational diabetes: results of a controlled, randomized, prospective study.
  99. The effect of maternal and child health and family planning services on mortality: is prevention enough?
  100. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
  101. Effects of long-term gestodene-containing oral contraceptive administration on hemostasis.
  102. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid.
  103. Effects of oral contraceptive pills on serum lipoproteins and triglycerides.
  104. Effects of oral contraceptives on carbohydrate and lipid metabolisms in a healthy population: the Telecom Study.
  105. Effects of oral contraceptives on lipid metabolism.
  106. Effects of steroidal contraceptives on gallbladder: a review.
  107. Effects of three combined oral contraceptives preparations containing desogestrel plus ethinyl estradiol on lipid metabolism in comparison with two levonorgestrel preparations.
  108. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials.
  109. The efficacy of the progestogen-only pill as a contraceptive method.
  110. Efficacy of three variations of periodic abstinence for family planning in Indonesia.
  111. Enhanced generation and resolution of fibrin in women above the age of 30 years using oral contraceptives low in estrogen.
  112. Epidemiology and aetiology of acute non-tuberculous salpingitis. A comparison between the early 1970s and the early 1980s with special reference to gonorrhea and use of intrauterine contraceptive devices.
  113. Estrogenic effect of gestodene- or desogestrel-containing oral contraceptives on lipoprotein metabolism.
  114. Evaluating the impact of a theory-based sexuality and contraceptive education program.
  115. The evolution of oral contraceptives. Maximizing efficacy, minimizing risks.
  116. Extending the duration of the pill-free interval during combined oral contraception.
  117. Family planning in Rwanda: status and prospects.
  118. Family planning in traditional markets in Nigeria.
  119. Fertility and family planning in Jordan: results from the 1985 Jordan husbands' fertility survey.
  120. The first pill-taking generation: past and present use of contraception amongst a cohort of women born in the early 1950s.
  121. Five years experience of intrauterine contraception with the Nova-T.
  122. A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis.
  123. Frequency of intercourse and contraceptive choice.
  124. Gastrointestinal metabolism of contraceptive steroids.
  125. Gonadotropin and estradiol secretion during the week of placebo therapy in oral contraceptive pill users.
  126. Gonadotropin suppression with oral contraceptives before in vitro fertilization.
  127. Growth inhibition of Candida albicans and other medically important yeasts by vaginal contraceptive products.
  128. Hemostasis profile in women taking low-dose oral contraceptives.
  129. Hemostatic changes in women using a monthly injectable contraceptive for one year.
  130. HIV/AIDS counselling and testing at a family planning clinic: a report of the first year of a new service in Glasgow.
  131. Hormonal postcoital contraception with an ethinylestradiol-norgestrel combination and two danazol regimens.
  132. The impact of public-sector expenditures for contraceptive services in California.
  133. The impact of service delivery frequency on family planning program output and efficiency.
  134. Incidence of uncomplicated genital infections in women using oral contraception or an intrauterine device: a prospective study.
  135. Influence of a triphasic oral contraceptive preparation on plasma lipids and lipoproteins.
  136. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea.
  137. Influence of modern low-dose oral contraceptives on hemostasis.
  138. Influence of oral contraceptives on coagulation tests in native blood and plasma.
  139. Influence of oral contraceptives on prognostic factors in breast cancer. [Zum Einfluss der Einnahme hormonaler Kontrazeptiva auf Prognosefaktoren beim Mammakarzinom.]
  140. Inhibition of ovulation by low-dose monophasic contraceptive containing gestodene.
  141. Initial acceptability of contraceptive implants in four developing countries.
  142. Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings.
  143. Is permanent contraception acceptable in sub-Saharan Africa?
  144. Islam and family planning acceptance in Bangladesh.
  145. Level of education, use of oral contraceptives and reproductive factors: the Tromso study.
  146. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the Copper T 380AG intrauterine devices: a five-year randomized study.
  147. Low-dose oral contraceptives and carbohydrate metabolism.
  148. Low-dose oral contraceptives lower plasma levels of apolipoprotein E.
  149. Low-income women's perceptions of family planning service alternatives.
  150. Mass media family planning promotion in three Nigeria cities.
  151. Maternal-child health and family planning: user perspectives and service constraints in rural Bangladesh.
  152. Mechanism of action of oral contraceptives on carbohydrate metabolism at the cellular level.
  153. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trail. III. The relationship between pregnancy rate and body weight.
  154. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects.
  155. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. II. Expulsions and removals.
  156. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. IV. Bleeding patterns.
  157. Multicentered clinical study of the metabolic effect of the monthly injectable contraceptive containing dihydroxyprogesterone acetophenide 150 mg + estradiol enanthate 10 mg.
  158. Oncogenic transformation by human papillomavirus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives.
  159. Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies.
  160. Oral contraception in disease states.
  161. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism.
  162. Oral contraceptive use and invasive cervical cancer.
  163. Oral contraceptive use and risk of invasive cervical cancer.
  164. Oral contraceptive use and the risk of myocardial infarction.
  165. Oral contraceptives and breast cancer.
  166. Oral contraceptives and breast cancer. Review and meta-analysis.
  167. Oral contraceptives and diabetes mellitus [reply]
  168. Oral contraceptives and myocardial infarction.
  169. Oral contraceptives in risk groups: exclusion or monitoring?
  170. Oral contraceptives use and liver tumours: a review.
  171. Oral contraceptives, lipoproteins, and atherosclerosis.
  172. Ovarian endocrine function through five years of continuous treatment with Norplant subdermal contraceptive implants.
  173. Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study.
  174. Perforation of the rectum by a Copper-T intra-uterine contraceptive device; a case report.
  175. Pharmacokinetics and pharmacodynamics of oral contraceptive steroids: factors influencing steroid metabolism.
  176. Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings.
  177. Pharmacokinetics of gestodene and ethinyl estradiol after oral administration of a monophasic contraceptive.
  178. Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women.
  179. Pituitary repetitive stimulation with GnRH/TRH in women treated with three different oral steroid contraceptives.
  180. Prevalence of bacterial vaginosis and its association with genital infections, inflammation, and contraceptive methods in women attending sexually transmitted disease and primary health clinics.
  181. Prostaglandins: PGF2 alpha, PGE2, 6-keto-PGF1 alpha and TXB2 serum levels in dysmenorrheic adolescents before, during and after treatment with oral contraceptives.
  182. Protein binding of active ingredients and comparison of serum ethinyl estradiol sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ethinyl estradiol (Femovan) or a combination of desogestrel/ethinyl estradiol (Marvelon) and single-dose ethinyl estradiol bioequivalence from both oral contraceptives.
  183. Public-sector savings resulting from expenditures for contraceptive services.
  184. The relationship between fertility and contraceptive prevalence in Zimbabwe.
  185. Reproductive mortality and its relation to different methods of birth control.
  186. Sexual behaviour, contraceptive practice and knowledge of reproductive biology among adolescent secondary school girls in Nairobi, Kenya.
  187. Some aspects of the relationship between oral contraceptives, lipid abnormalities, and cardiovascular disease.
  188. Steroidal contraceptives and changes in individual plasma phospholipids: possible role in thrombosis.
  189. Studies on the mechanism of action of oral contraceptives with regard to fibrinolytic variables.
  190. Supportive European data on a new oral contraceptive containing norgestimate.
  191. Surgical contraception after cesarean section. [Khirurgichna kontratseptsiia sled tsezarevo sechenie.]
  192. Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives.
  193. Trends in use of oral contraceptives in Britain.
  194. Trends in use of oral contraceptives--data from the 1987 National Health Interview Survey.
  195. United States and Denmark: different approaches to health care and family planning.
  196. Urinary hormonal profile during the first cycle of low-dose oral contraceptive pills in women.
  197. Use of condoms as contraceptive and disease preventive measures among residents of Jos, northern Nigeria.
  198. Use of contraceptives by women of upper socioeconomic status.
  199. Use of oral contraceptives in middle-aged women in the GDR. [Zur Anwendung oraler Kontrazeptiva in der DDR bei Frauen mittleren Alters.]
  200. The use of the triphasic contraceptive preparation trisiston for therapeutic purposes. [Prilozhenie na trifazniia kontratseptiven preparat trisiston za lechebni tseli.]
  201. In which way do cigarette smoking and the various methods of contraception play a role in the development of cervical cancer and its pre-stages? [Welche Rolle spielen "Zigarettenrauchen" und die verschiedenen kontrazeptiven Methoden bei der Entstehung des Zervixkarzinoms und seiner Vorstufen?]
  202. Results of a physician survey on knowledge and attitude toward natural family planning in the Federal Republic of Germany in 1988. [Ergebnisse einer Arzte-Befragung uber Kenntnisstand und Einstellung zur naturlichen Familienplanung in der Bundesrepublik Deutschland 1988.]
  203. Results of a physicians' survey on the status of knowledge of and attitudes toward natural family planning in the Federal Republic of Germany, 1988 (letter)
  204. Review of family planning: current situation and trends in industrialized countries.
  205. Review of lipids, cardiovascular disease, and oral contraceptives [letter]
  206. Review of lipids, cardiovascular disease, and oral contraceptives. Reply of the author [letter]
  207. Revolution and counter-revolution: contraceptives and family planning in the 1990s.
  208. Rhabdomyosarcoma of the liver associated with long-term oral contraceptive use. Possible role of estrogens in the genesis of embryologically distinct liver tumors.
  209. Risk of chlamydial PID and oral contraceptives [letter]
  210. Risk of chlamydial PID and oral contraceptives [letter]
  211. Risk of chlamydial PID and oral contraceptives. In reply [letter]
  212. Risks and complications of intrauterine contraception. [Rizika a komplikace nitrodelozni antikoncepce.]
  213. The role of adhesion in the migration of bacteria along intrauterine contraceptive device polymer monofilaments.
  214. Role of incentives and disincentives in promotion of family planning in corporate sector.
  215. The role of marketing research in international contraceptive social marketing programs.
  216. Role of planned parenthood for enrichment of the quality of life in Sri Lanka.
  217. The role of research in contraceptive introduction.
  218. Role of rural women in the family decision-making process with special reference to acceptance of family planning.
  219. The role of the male partner in contraception and the decision on abortion. [Mannlig partners rolle ved prevensjonssvikt og abortvalg. En sporreundersokelse blant abortsokende kvinner og deres mannlige partnere.]
  220. S.R.I. Female Omnibus Blue Circle Contraceptive Study. Management summary.
  221. Safety of intrauterine contraception.
  222. Safety, acceptability and use of hormonal contraceptives.
  223. Saving life and making it better. The evolution of the Indonesian Family Planning Program.
  224. A scale to measure microbehaviors of oral contraceptive pill use.
  225. Seasonality of births in the North West Province, Cameroon: implications for family planning programme.
  226. Secondary review of family planning contraceptive KAP data in Uganda. Final report.
  227. Selected nutrient intake of family planning participants within the Mississippi State Department of Health.
  228. Selection, change, and discontinuation of contraceptive methods in Trinidad and Tobago.
  229. Self-efficacy training: its impact upon contraception and depression among a sample of urban adolescent females.
  230. Service provider's guide to family planning.

     

  231. Service providers attitudes towards and stocking patterns of Blue Circle contraceptives. Management summary.
  232. Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal.
  233. Sexual activity, contraception and unwanted pregnancy at puberty and adolescence. [Seksualna aktivnost, kontratseptsiia i nezhelana bremennost v pubertetno-iunosheskata vuzrast.]
  234. Sexual behavior and acceptance of family planning in the Mayan-Quiche population of Guatemala. [Comportamiento sexual y aceptacion de la planificacion familiar en la poblacion Maya-Quiche Guatemala.]
  235. Assessment of family planning service provision and training of family planning service providers in Turkey.
  236. Assessment of the fertility impact of family planning programmes in Egypt.
  237. Association of oral contraceptive use and human papillomaviruses in invasive cervical cancers.
  238. The association of oral contraceptives, trichomonas vaginalis infection and pelvic inflammatory disease.
  239. Attitudes toward consequences of pregnancy in young women attending a family planning clinic.
  240. Attitudes toward voluntary surgical contraception among health personnel from eight sites in Zaire.
  241. Auditory sensitivity and tone-sequence reproduction in oral contraceptive users and nonusers.
  242. Back to "hell?" The threatening family planning crisis in Poland.
  243. Bangladesh Contraceptive Prevalence Survey--1989: final report.
  244. Barrier and spermicidal contraceptive methods and risk of invasive cervical cancer.
  245. Barrier contraception increases the risk of pre-eclampsia. [Barierova antikoncepce zvysuje riziko preeklampsie.]
  246. Barrier contraception.
  247. Barrier contraceptives and sexually transmitted diseases.
  248. Barrier contraceptives and the interaction between HIV and other sexually transmitted diseases.
  249. Barrier methods of contraception.
  250. Belief systems concerning family planning, child spacing and parity. A descriptive study to describe the beliefs and attitudes of pastoral Maasai concerning family planning, child spacing and parity.
  251. Benefits and risks of oral contraceptives.
  252. Benzalkonium in local contraception and sexually transmitted diseases. [Il benzalconio nella contraccezione locale e nelle MTS.]
  253. Birth control and low-income Mexican-American women: the impact of three values.
  254. Birth control vaccines and immunological approaches to the therapy of noninfectious diseases.
  255. Birth control: the example of Verdun in the second half of the eighteenth century. [La limitation des naissances: l'exemple de Verdun dans la deuxieme moitie du XVIIIe siecle.]
  256. The birth of birth control.
  257. Birth spacing decision: issues and views on family planning services in Kabwe District, Zambia [letter]
  258. Births averted due to the gross impact of contraceptive use in Egypt.
  259. Bladder stone in a human female: the case of an abnormally located intrauterine contraceptive device.
  260. Blood pressure behavior with hormonal contraception. [Blutdruckverhalten wahrend der Empfangnisverhutung mit hormonalen Kontrazeptiva.]
  261. Blood tests and oral contraception [letter]
  262. Blue Circle Contraceptives Social Marketing Project, Indonesia.
  263. Bolivia: family planning goes public. A case study of the communication process at work.
  264. Brazil Contraceptive Social Marketing Program evaluation.
  265. 1989 Haiti National Contraceptive Prevalence Survey, preliminary English language report.
  266. 1991 contraceptive procurement tables (CPTs). Guidance.
  267. A.I.D. assistance to family planning in Kenya.
  268. Abortion and family planning bibliography for 1987.
  269. Abortion as a method of birth control. [Abortus kao metod kontrole radanja.]
  270. Acceptability and cost effectiveness of postpartum contraception in Lima, Peru.
  271. Achievements in China's family planning work shown by fertility and birth control sampling surveys.
  272. Achieving financial self-reliance. A manual for managers of non-governmental organizations involved in family planning.
  273. Adolescence and contraception. 1. A study of knowledge and use among users of prenatal or abortion services. [Adolescencia e anticoncepcao. 1. Estudo de conhecimento e uso em puerperas internadas por parto ou aborto.]
  274. Adolescent contraceptive risk-taking behavior: a social psychological model of females' use of and compliance with birth control.
  275. Adolescent pregnancy and contraception in greater Banjul. Young people need precise information. [Grossesse de l'adolescente et contraception dans l'agglomeration de Banjul. Les jeunes ont besoin d'une information precise.]
  276. Adolescents and condom use: the difference between contraception and S.T.D. - A.I.D.S. prevention.
  277. Adolescents and contraception: use of contraception by Norwegian adolescents at most recent intercourse and during casual sex. [Ungdom og prevensjon -- bruk av prevensjon ved siste samleie og ved tilfeldig sex blant norsk ungdom.]
  278. Adoption of family planning practices and associated factors in Paharganj area of Delhi.
  279. African countries must increase support for family planning programmes.
  280. The agricultural approach to rural family planning in the Philippines.
  281. AIDS and contraception -- increased use of condoms at first intercourse among Norwegian adolescents. [AIDS og prevensjon -- oket bruk av kondom ved forste samleie blant norsk ungdom.]
  282. AIDS and contraception.
  283. AIDS and family planning: married, divorced or just living together?
  284. AIDS and family planning: Thailand conference breaks new ground.
  285. AIDS prevention in family planning programs.
  286. AIDS prevention: guidelines for MCH/FP programme managers, Vol. 1: AIDS and family planning.
  287. AIDS prevention: guidelines for MCH/FP programme managers. I. AIDS and family planning.
  288. Altered growth hormone secretion during oral contraception.
  289. An alternative methodological approach for studies in family planning.
  290. An analysis of the relationships between selected situational and demographic variables influencing contraceptive use and pregnancy risk among adolescents.
  291. Antifertility effects of neem (Azadirachta indica) oil by single intrauterine administration: a novel method for contraception.
  292. An approach for the study of infertility following prior contraceptive use using data from large individual level surveys.
  293. Appropriate operations research strategies for family planning IEC programs.
  294. Appropriate technology in maternal and child health and family planning.
  295. Are contraceptives abortifacient?
  296. Asia Family Planning Operations Research Project: recommendations based on a review of the current project.
  297. Breast cancer and combined oral contraceptives [letter]
  298. Breast cancer and early oral contraceptive use: studies from the Slone Epidemiology Unit.
  299. Breast cancer and oral contraceptives.
  300. Breast carcinoma: advice concerning aftercare, hormonal contraception or estrogen replacement and pregnancy. [Mammacarcinoom; adviezen ten aanzien van nacontrole, hormonale anticonceptie of substitutie met oestrogenen, en zwangerschap.]
  301. Breast epithelial responses and steroid receptors during oral contraceptive use.
  302. Breast-feeding and the family planning sector's initiative in Indonesia.
  303. Breastfeeding and contraception.
  304. Breastfeeding as a postpartum contraceptive method.
  305. Bucharest's first family planning clinic since the revolution.
  306. Budd-Chiari syndrome, pulmonary thromboembolism, and deep venous thrombosis associated with "lupus anticoagulant" and recent use of oral contraceptives. [Sindrome de Budd-Chiari, tromboembolismo pulmonar y trombosiss venosa profunda, asociado con "anticoagulante lupico" y uso reciente de anticonceptivos orales.]
  307. Cardiovascular diseases and oral contraceptives: risks and benefits. [Kreislauferkrankungen unter oralen Kontrazeptiva: Risiken und Nutzen.]
  308. Cardiovascular safety of current oral contraceptives for nonsmoking women.
  309. Caribbean family planning guide: a self-instructional manual for health professionals.
  310. Cash payments for family planning in Bangladesh.
  311. Cervical neoplasms and oral contraceptives.
  312. Changes in carbohydrate and lipid metabolism and modification of diabetes mellitus by hormonal contraception. [Veranderungen im Kohlenhydrat- und Lipidstoffwechsel sowie Beeinflussung des Diabetes mellitus durch hormonale Kontrazeptiva.]
  313. Changes in coagulation and fibrinolysis variables during use of two oral contraceptives containing the same dose of ethinyl estradiol and either gestodene or desogestrel.
  314. Changes in fertility in rural China: a simulated micro-analysis of the interactions between the demand and supply of children, and the family planning policy.
  315. Changing from an oral contraceptive to hormone replacement therapy for menopause.
  316. Characteristics of the clinical course of acute adnexitis in patients using intrauterine contraceptive devices (IUD) [Osobennosti klinicheskogo techeniia ostrykh vospalitelnykh zabolevanii pridatkov matki na fone ispolzovaniia vnutri-matochnykh kontratseptivov.]
  317. Charting a course for family planning communication in Cameroun. Results of focus group discussion research.
  318. Child spacing and awareness of family planning among refugees: evidence from Central America.
  319. Child survival: the role of family planning.
  320. China, India, Philippines, Sri Lanka, Viet Nam. Knowledge and attitudes of grassroots family planning workers about contraceptive methods.
  321. Chlamydia screening -- should it be offered as a routine? A feasibility study in family planning clinics.
  322. Chlamydia trachomatis and family planning [editorial]
  323. Choice and challenge: global teamwork in developing a contraceptive implant.
  324. Choices: contraception, pregnancy, birth, and abortion.
  325. Cigarette smoking and oral contraceptive use influence women's lipid, lipoprotein, and cardiovascular responses during stress.
  326. Circular on census and family planning of 1990.
  327. Client autonomy among natural family planning users in Mauritius.
  328. Clinical aspects of the relationship between oral contraceptives and abnormalities of the hemostatic system: relation to the development of cardiovascular disease.
  329. Clinical pharmacological study of Tri-Regol tablets (new oral triphasic contraceptive) [A Tri-Regol tabletta klinikai- farmakologiai vizsgalata (Uj, oralis, trifazisos kontraceptivum)]
  330. The clinical relevance of oral contraceptive pill-induced plasma lipid changes: facts and fiction.
  331. Clinical study of the use of a new triphasic oral contraceptive. [Studio clinico sull'uso di una nuova pillola trifasica.]
  332. Coagulation profile in women on low-dose oral contraceptive pills.
  333. Coitus and contraception: the utility of DHS data on sexual behavior for family planning programs.
  334. Collection of survey data on contraception: experimental field studies in Peru and the Dominican Republic.
  335. College student contraceptive use: a multivariate analysis.
  336. Combination oral contraceptives and cancer risk.
  337. The combined oral contraceptive. A practical guide.
  338. Coming of age in the era of AIDS: puberty, sexuality, and contraception.
  339. Comments on estimations of family planning effects.
  340. Communicating with adolescents. Telephone counseling and adolescent health clinic services of the Japan Family Planning Association.
  341. Community based distribution of family planning services: the international experiences with selected issues.
  342. Community characteristics and their influence on contraceptive method use among married White women in the U.S.
  343. Community health nurses and family planning services for men.
  344. Community influences on the sexual and contraceptive behaviors of adolescent women.
  345. Community medical offices: a family planning and health care model for a poor, urban population. [Los consultorios comunitarios. Un modelo de planeacion familiar y atencion a la salud para poblacion marginada de zonas urbanas.]
  346. Community participation in family planning: a case study of Kundam Integrated Rural Project.
  347. Community participation in maternal and child health / family planning programmes. An analysis based on case study materials.
  348. Community-based family planning in Africa.
  349. A comparative study of health distress and sex behavioural attitude of family planning adopters and non-adopters.
  350. Comparative study on the acceptance and use of contraceptive methods in a rural population in Kelantan.
  351. A Comparison of Male and Female Community Based Distributors of Contraceptives, Contract Nos. CI87.74A/CI88.08A and CI87.73A, November 15, 1987 - August 31, 1989. Final report.
  352. Comparison of serum ethinyl estradiol, sex-hormone-binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral contraceptives.
  353. Comparison of the lipoprotein and hemostatic changes after a triphasic and a monophasic low dose oral contraceptive in premenopausal middle-aged women.
  354. Complications caused by intrauterine contraceptive devices. [Komplikationer ved kontraception med intrauterin spiral.]
  355. Consent and confidentiality: critical issues in providing contraceptive care.
  356. Consultants in medical gynaecology -- a career option for our family planning doctors?
  357. Contraception and adolescents.
  358. Contraception and interaction among Dutch boys and girls.
  359. Contraception and pregnancy in systemic lupus erythematosus. [Contraception et grossesse au cours du lupus erythemateux systemique.]
  360. Contraception and risk factors for diseases of the uterine cervix. [Antikoncepce a rizikove faktory vzniku chorob delozniho hrdla.]
  361. Contraception and tubal sterility of infective origin. [Contraception et sterilite tubaire d'origine infectieuse.]
  362. Contraception and women of the third world: a question of reproductive autonomy. [La contraception et les femmes du tiers-monde: une question d'autonomie reproductive.]
  363. Contraception for adolescents and its effect on menstruation. [Die Kontrazeption Jugendlicher und ihre Auswirkungen auf das Zyklusgeschehen.]
  364. Contraception for postpartum use: non-hormonal methods -- intrauterine devices.
  365. Contraception for the diabetic woman. [Contraception chez la femme diabetique.]
  366. Contraception for the young.
  367. Contraception from the aspect of present legal reforms. [Antikoncepce z hlediska soucasne pravni upravy.]
  368. Contraception guidance in general practice. A questionnaire study in Nordland, Troms and Finnmark. [Prevensjonsveiledning i allmennpraksis. En sporreskjemaundersokelse i Nordland, Troms og Finnmark.]
  369. Contraception handbook. Toward healthy family planning. [Manual de anticoncepcao. Para um planejamento familiar sadio.]
  370. Contraception in Austria. [Kontrazeption in Osterreich.]
  371. Contraception in Western Europe: a current appraisal.
  372. Contraception survey: Denmark 1988.
  373. Contraception while breastfeeding.
  374. Contraception, family planning and human rights.
  375. Contraception.
  376. Contraception: a guide to birth control methods.
  377. Contraception: barriers and spermicides, periodic abstinence, and intrauterine devices.
  378. Contraception: problem cases. [Les contraceptions difficiles.]
  379. Contraception: search for safety.
  380. Contraceptive and sexual behavior of black female adolescents. A test of a social-psychological theoretical model.
  381. Contraceptive attitudes and intention to use condoms in sexually experienced and inexperienced adolescent males.
  382. Contraceptive behavior among sexually active Hispanic adolescents.
  383. Contraceptive choice in Lagos, Nigeria.
  384. Contraceptive choice, shift and use continuation: a prospective study in Gujarat.
  385. Contraceptive continuation and reasons for discontinuation in Kinshasa, Zaire.
  386. Contraceptive development lags in U.S.
  387. Contraceptive development: why the snail's pace?
  388. Contraceptive discontinuation in Peru: patterns and demographic implications.
  389. Contraceptive failure in the adolescent: analysis of 720 cases of induced abortion. [L'echec de la contraception chez l'adolescente: analyse de 720 cas d'interruptions de grossesse.]
  390. Contraceptive intention behavior in rural Bangladesh: factors in the diffusion of an innovation.
  391. Contraceptive marketing in Zaire, 1988-1989: a sentinel site survey. [Vente des produits contraceptifs au Zaire, 1988-1989: une etude de postes sentinelles.]
  392. The contraceptive needs of midlife women.
  393. Contraceptive options for women in their 40s.
  394. The contraceptive pill and cancer.
  395. Contraceptive pills and congenital abnormalities (letter) [A fogamzasgatlo tablettak es a veleszuletett rendellenessegek.]
  396. Contraceptive practice in Mexico: two five-year periods, two different patterns (1976-1977 to 1987) [La practica anticonceptiva en Mexico: dos quinquenios, dos patrones diferentes (1976-1977 a 1987)]
  397. Contraceptive prevalence in Antigua.

     

  398. Contraceptive prevalence in St. Vincent.
  399. Contraceptive retail markets in Sri Lanka.
  400. The contraceptive revolution in Canada. [Revolutions contraceptives au Canada.]
  401. Contraceptive services for Asian women in the UK: a review.
  402. Contraceptive services for Asian women in UK [letter]
  403. Contraceptive social marketing in Nepal: consumer and retailer knowledge, needs and experience.
  404. Contraceptive steroids as a risk factor for hepatocellular carcinoma: a case/control study in South African black women.
  405. The contraceptive supply cycle and condom distribution: the Pathfinder Fund's experience.
  406. Contraceptive technology, 1990-1992, 15th rev. edition.
  407. Contraceptive use amongst urban and rural youths in South Africa -- a comparative study.
  408. Contraceptive use and counseling before and after an abortion in Ohio, 1981 and 1986.
  409. Contraceptive use dynamics of couples availing of services from government family planning clinics -- a case study of Orissa.
  410. Contraceptive use for Planned Parenthood patients.
  411. Contraceptive use in low-fertility societies: estimates from a dynamic model. Draft: Work in progress.
  412. Contraceptive use in the United States, 1973-88.
  413. Contraceptive use, sensation seeking and adolescent egocentrism.
  414. Contraceptive use: the shifting patterns from one method to another in east, central and southern Africa.
  415. Contraceptives and ischemic heart disease. [Contraceptivos y cardiopatia isquemica.]
  416. Contraceptives and women's complaints: preliminary results from the post-marketing surveillance of Norplant. International Collaborative Surveillance of Norplant.
  417. Contraceptives versus abortifacients [editorial]
  418. Contraceptives, their health benefits and hazards.
  419. Contraceptives.
  420. Contraceptives: usage and attitude study.
  421. The contribution of multi-round Demographic and Health Surveys and Contraceptive Prevalence Surveys to management information systems.
  422. The contribution of NGOs to the Family Planning Program.
  423. The contribution of other government agencies to the Family Planning Program.
  424. The contribution of the Department of Health to the Philippine Family Planning Program.
  425. Coordination between NGOs and the MOHFP in the delivery of family planning services in rural Bangladesh.
  426. The correlates of continuity in contraceptive use.
  427. Correlates of contraceptive method choice in Indonesia.
  428. Correlates of short inter-birth intervals in peninsular Malaysia: their pathways of influence through breastfeeding and contraceptive use.
  429. Correlation between contraceptive method and abnormal vaginal discharge.
  430. The cost-benefit of publicly funded family planning services.
  431. A cost-benefit study of the family planning program of Benguet Corporation -- Benguet Gold Operations. Part I: Retrospective study. 1972-1987.
  432. Cote d'Ivoire. Finalization of Central Region Family Planning Promotion Project.
  433. Creating a strategy for systems change: the Nigeria Family Planning Management Trainers Network.
  434. Current approaches to strengthening the management of national maternal / child health and family planning programs.
  435. The current family planning debate in Soviet Central Asia.
  436. Current status of oral contraception and new developments: proceedings of an international symposium at the VII World Congress on Human Reproduction, Helsinki, Finland, June 26-July 1, 1990.
  437. Cycle control with lower-dose formulations of oral contraceptives.
  438. Cytogenetic study of blood in women who had used oral contraceptives.
  439. Dalkon shield IUD survivors: a case study of contraceptive tragedy and an emerging social protest movement, 1986-1989.
  440. Decision No. 90-53 AT of 12 April 1990 creating a high council for family planning. [Deliberation No. 90-53 AT du 12 avril 1990 portant creation d'un haut conseil de la planification familiale.]
  441. Decision on family planning work of 7 March 1990.
  442. Declaration of the National Seminar for Increasing the Role of the Ulama within family planning movement.
  443. Deep vein thrombophlebitis of a leg in a young female with heterozygous Protein C deficiency taking oral contraceptives [letter]
  444. Demographic and Health Surveys - Phase II. Interviewer's manual for use with model "B" questionnaire for low contraceptive prevalence countries.
  445. Demographic and Health Surveys -- Phase II. Interviewer's manual for use with model "A" questionnaire for high contraceptive prevalence countries.
  446. Demographic and Health Surveys -- Phase II. Model "A" questionnaire with commentary for high contraceptive prevalence countries.
  447. Demographic and Health Surveys -- Phase II. Model "B" questionnaire with commentary for low contraceptive prevalence countries.
  448. The demographic impact of family planning programs.
  449. Demonstrating demand for family planning: creating a supportive environment through operations research.
  450. Determinants of contraceptive method choice for women in municipal and non-municipal areas of Thailand.
  451. Determinants of contraceptive switching behavior in rural Sri Lanka.
  452. Determinants of contraceptive use and method choice among single women in the United States.
  453. Determinants of contraceptive use dynamics in rural Bangladesh. Executive summary.
  454. Determinants of family planning clinic performance in Cebu City, the Philippines.
  455. Developing a self-financing, factory-based contraceptive distribution project in St. Lucia.
  456. Developing contraceptive social marketing strategy in Indonesia: the Dualima experience.
  457. Developing management information systems in governmental and private sector family planning and health organizations.
  458. Developing new contraceptives: obstacles and opportunities.
  459. The development of a management information system for the family planning program in Indonesia.
  460. Development of a voluntary surgical contraception program in Rwanda. [Le developpement du programme de contraception chirurgicale volontaire au Rwanda.]
  461. Development of antisperm contraceptive vaccine for humans: why and how?
  462. Development of permanent and longterm contraception in Nigeria, 1986-1990. Report of a conference held at the Durbar Hotel, Kaduna, Nigeria, August 7-10, 1990.
  463. The development of population and family planning policies.
  464. Development of steroidal contraception. [Entwicklung der Kontrazeption mit steroiden.]
  465. Diffusion and adoption of contraceptive technology in developing countries. Revised.
  466. A diffusion of innovations model applied to family planning education in Honduras.
  467. Diminished incidence of severe rheumatoid arthritis associated with oral contraceptive use.
  468. Diplomate of Enfermary (nurse) Dur-y in municipal family planning.
  469. Directory of training courses in family planning and maternal and child health. 1990-91 edition.
  470. Do male and female physicians give the same contraceptive guidance? [Gir mannlige og kvinnelige leger lik Prevensjonsveiledning?]
  471. Do oral contraceptives increase blood pressure and serum total cholesterol in young women?
  472. Drawing attention to family planning.
  473. The dynamics of contraception in rural and urban Egypt.
  474. The dynamics of contraceptive use in Mexico. [Dinamica del uso de metodos anticonceptivos en Mexico.]
  475. Dynamics of the cervical mucosae during hormonal contraception by low-dose estrogens. A controlled prospective clinical study. [Dinamica delle mucose cervicali in corso di contraccezione ormonale a basso dosaggio di estrogeni. Studio clinico prospettico controllato.]
  476. Economic development, contraception and fertility decline in Mexico.
  477. The economics of family planning. Draft.
  478. Editorial: relevance of biological properties of progestogen of oral contraceptives in treatment of androgen excess symptoms.
  479. Education and contraceptive evolution among the Yoruba.
  480. The effect of a triphasic oral contraceptive on serum glucose and lipids in Egyptian acceptors.
  481. The effect of child mortality on fertility and family planning practice.
  482. The effect of contraceptive suppository of morrhuatic acid on lactobacilli in the vagina.
  483. Effect of hormonal contraceptives on the voice. [Einfluss hormonaler Kontrazeptiva auf die Stimme.]
  484. The effect of long term use of oral contraceptive pills on lipid metabolism.
  485. Effect of menstrual cycle phase and oral contraceptive use on serum lithium levels after a loading dose of lithium in normal women.
  486. Effect of nurse-client transaction on female adolescents' contraceptive perceptions and adherence.
  487. The effect of olestra on systemic levels of oral contraceptives.
  488. The effect of oral contraceptive agents with and without supplemental calcium on calcium metabolism and urinary hydroxyproline excretion in young women.
  489. Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon.
  490. The effect of oral contraceptive use and pregnancy on the daily rhythm of cortisol and cortisone.
  491. Effect of oral contraceptives on developmental disorders and neonatal sex ratio. [Az oralis kontraceptivumok hatasa a fejlodesi rendellenessegek es az ujszulottek nemi aranyanak alakulasara.]
  492. Effect of sex education on the sexual and contraceptive practices of female teenagers in Mexico City.
  493. Effective family planning service components: global lessons from operations research.
  494. Effectiveness and safety of a new combined oral contraceptive containing 75 micrograms gestodene and 30 micrograms ethinyl estradiol in Mexican women. [Efectividad y seguridad de un nuevo preparado anticonceptivo oral combinado 75 mcg gestodeno mas 30 mcg etinilestradiol en mujeres mexicanas.]
  495. Effectiveness of female voluntary surgical contraception. [Eficacia da anticoncepcao cirurgica voluntaria feminina.]
  496. Effectiveness of progestogen only oral contraceptives [letter]
  497. Effectiveness of vaginal contraception in prevention of sexually transmitted diseases.
  498. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
  499. The effects of funding cuts on the California family planning program, 1989-1990.
  500. Effects of husband-wife communication on family planning intentions and behavior: a cross-sectional study of husbands and wives living in union in Lusaka, Zambia.

To view other lists of the current category of articles, please visit "Category Lists Homepage"


Web PubHealth.info

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.